NuP-3 is a potent, selective MAPK13 and MAPK14 inhibitor with IC50 of 7 and 14 nM, respectively.
NuP-3 treatment markedly inhibited MUC5AC and CLCA1 induction in hTECs cultured under air-liquid interface conditions with IL-13 stimulation, but not the MAPK14 inhibitor NuP-43 (BIRB-796, Cat. PC-42520).
NuP-3 demonstrated similarly effective blockade of IL-13-stimulated MUC5AC and CLCA1 mRNA expression, without evidence of cell toxicity.
NuP-3 treatment effectively attenuates respiratory inflammation and mucus production in new minipig models of airway disease after type-2 cytokine challenge or respiratory viral infection.
NuP-3 also down-regulates biomarkers linked to basal-epithelial stem cell activation as an upstream site for target engagement.
